77
Participants
Start Date
February 26, 2015
Primary Completion Date
November 30, 2016
Study Completion Date
March 26, 2019
Crenezumab dose level 1
Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Crenezumab dose level 2
Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Crenezumb dose level 3
Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
Placebo
Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
Columbia University Medical Center, New York
UNiversity of Rochester, Rochester
Roper St. Francis Healthcare; Clinical Biotechnology Research Institute, Charleston
Bioclinica The Villages, The Villages
Bioclinica Orlando, Orlando
Miami Jewish Health Systems, Miami
Brain Matters Research, Inc., Delray Beach
Hattiesburg Clinic, Hattiesburg
Indiana University School Of Medicine; Department Of Neurology, Indianapolis
Millennium Psychiatric Associates, LLC, St Louis
Mayo Clinic Scottsdale, Phoenix
UCSF - Memory and Aging Center, San Francisco
Rhode Island Mood & Memory Research Institute, East Providence
Lead Sponsor
Genentech, Inc.
INDUSTRY